InfuSystem Holdings, Inc. (NYSE:INFU) Shares Bought by State Street Corp

State Street Corp raised its position in InfuSystem Holdings, Inc. (NYSE:INFU) by 1.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 267,012 shares of the company’s stock after purchasing an additional 3,019 shares during the period. State Street Corp owned 1.26% of InfuSystem worth $1,789,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of INFU. BNP Paribas Financial Markets increased its holdings in InfuSystem by 66.4% in the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after buying an additional 1,626 shares during the last quarter. Williams & Novak LLC acquired a new position in shares of InfuSystem during the 3rd quarter worth about $70,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of InfuSystem in the 3rd quarter valued at about $87,000. Rhumbline Advisers raised its position in shares of InfuSystem by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock worth $121,000 after acquiring an additional 2,145 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in InfuSystem during the second quarter worth approximately $131,000. 71.13% of the stock is owned by hedge funds and other institutional investors.

InfuSystem Stock Up 5.6 %

Shares of NYSE INFU opened at $8.45 on Thursday. The firm has a 50-day moving average price of $8.23. The firm has a market cap of $179.68 million, a PE ratio of 140.86 and a beta of 1.53. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 52-week low of $5.74 and a 52-week high of $10.58.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. B. Riley initiated coverage on shares of InfuSystem in a research note on Thursday, September 26th. They issued a “buy” rating and a $13.00 price target on the stock. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th.

Insider Activity

In other news, CEO Richard Dilorio sold 20,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.32, for a total transaction of $186,400.00. Following the completion of the sale, the chief executive officer now owns 436,659 shares in the company, valued at approximately $4,069,661.88. This represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.20% of the company’s stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.